Zobrazeno 1 - 8
of 8
pro vyhledávání: '"L. Gashonia"'
Autor:
Lindsey E. Roeker, Andrew D. Zelenetz, AnnaLynn M. Williams, Andre Goy, Paul M. Barr, Hande H. Tuncer, Stephen J. Schuster, Joshua Felsenfeld, Brian T. Hill, Alan P Skarbnik, Mansi Malhotra, Colleen Dorsey, Christina Howlett, Allison M. Winter, Ryan Jacobs, Naveed Ali, Nirav N. Shah, Anthony R. Mato, Krista Isaac, Jeffrey J. Pu, Nicole Lamanna, Chaitra S. Ujjani, Melissa Yacur, Arun K Singavi, Eve Tranchito, Peter V. Pickens, Richard R. Furman, Kaitlin Kennard, John N. Allan, Andrea Sitlinger, Sirin Khajavian, Meghan C. Thompson, John M. Pagel, Clive S. Zent, Neil Bailey, Alison R. Sehgal, Danielle M. Brander, Hanna Weissbrot, Chadi Nabhan, Mazyar Shadman, Jakub Svoboda, Frederick Lansigan, Bruce D. Cheson, L. Gashonia, Bhavisha A Patel, Christine A. Garcia, Joanna Rhodes, Timothy F. Burns
Publikováno v:
Haematologica
Venetoclax is a BCL2 inhibitor approved for 17p-deleted relapsed/refractory chronic lymphocytic leukemia with activity following kinase inhibitors. We conducted a multicenter retrospective cohort analysis of patients with chronic lymphocytic leukemia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b172b0c8dcf6563b824e875a0e38f19
https://doi.org/10.3324/haematol.2018.193615
https://doi.org/10.3324/haematol.2018.193615
Autor:
L. Gashonia, Pavel Kiselev, Kaitlin Kennard, Christina Howlett, Allison M. Winter, Andre Goy, Clive S. Zent, Danielle M. Brander, Stephen J. Schuster, Chadi Nabhan, Kenneth A. Foon, Allan-Louie Cruz, Catherine Daniel, David F. Claxton, Brian T. Hill, Alan P Skarbnik, Paul M. Barr, Colleen Timlin, K. Isaac, Nicole Lamanna, Molly Fanning, Chaitra S. Ujjani, J. Lenhart, Melissa Yacur, Bruce D. Cheson, Jeffrey J. Pu, Jakub Svoboda, S. Henick Bachow, Anthony R. Mato
Publikováno v:
Annals of Oncology. 28:1050-1056
Ibrutinib, idelalisib, and venetoclax are approved for treating CLL patients in the United States. However, there is no guidance as to their optimal sequence.We conducted a multicenter, retrospective analysis of CLL patients treated with kinase inhib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4bb1ae7c7a44ea0b20dfa07d9977a75
https://doi.org/10.1093/annonc/mdx031
https://doi.org/10.1093/annonc/mdx031
Autor:
Isaac Deonarine, M. Sarraf Yazdy, Colleen Dorsey, Bruce D. Cheson, Hannah Morse, Joseph R. Carver, Anthony R. Mato, Lindsey E. Roeker, Mayur Narkhede, Kristen E. Battiato, Kaitlin Kennard, Julie Goodfriend, L. Gashonia, Joanna Rhodes, Stephen J. Schuster
Publikováno v:
Hematological Oncology. 37:212-213
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d0e57772e5c1e168546b3a33988c8712
https://doi.org/10.1002/hon.28_2630
https://doi.org/10.1002/hon.28_2630
Autor:
Hannah Morse, Stephen J. Schuster, M. Peterson, Anthony R. Mato, B. Cheson, Julie Goodfriend, Joseph R. Carver, Lindsey E. Roeker, Mayur Narkhede, M Yazdy, Colleen Dorsey, Joanna Rhodes, Kristen E. Battiato, Kaitlin Kennard, L. Gashonia
Publikováno v:
HemaSphere. 3:145
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1157e6d8ad5ac0fbccad550a36579553
https://doi.org/10.1097/01.hs9.0000559756.43817.f1
https://doi.org/10.1097/01.hs9.0000559756.43817.f1
Autor:
Jakub Svoboda, Stephen J. Schuster, Chadi Nabhan, Mitchell E. Hughes, Joseph R. Carver, L. Gashonia, Naveed Ali, Anthony R. Mato, Peter V. Pickens, Joanna Rhodes, Suparna C. Clasen
Publikováno v:
Cancer Biology & Therapy. 19:1-2
Results from several recent studies in chronic lymphocytic leukemia (CLL) have demonstrated an association between ibrutinib exposure and the development of atrial fibrillation, estimated incidence of 11% with long-term follow up. This is a common ca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::003e56befc28b73c19d7557793f765c3
https://doi.org/10.1080/15384047.2017.1394554
https://doi.org/10.1080/15384047.2017.1394554
Autor:
Chadi Nabhan, Kaitlin Kennard, Rupal O'Quinn, Catherine Daniel, Joseph R. Carver, L. Gashonia, Anthony R. Mato, Krista Isaac, Stephen J. Schuster, Molly Fanning, Donald E. Tsai, Mitchell E. Hughes, Sunita D. Nasta, Jakub Svoboda, Daniel J. Landsburg, Suparna C. Clasen
Publikováno v:
Journal of Clinical Oncology. 35:7525-7525
7525 Background: Cardiovascular (CV) complications associated with ibrutinib (Ibr) include hypertension (HTN) and atrial fibrillation (AFIB) (incidence 26% and 9%, OBrien, ASH 2016). Unlike clinical trials, Ibr toxicities are the most common reasons
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e6c58bda25c2975f359f1ce3881fa89b
https://doi.org/10.1200/jco.2017.35.15_suppl.7525
https://doi.org/10.1200/jco.2017.35.15_suppl.7525
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.